Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

New application of HLA-B* 13 gene

A kind of HLA-B, allele technology, applied in the new use of HLA-B*13:02 gene, HLA-B*13:01 gene field

Active Publication Date: 2020-12-29
FUDAN UNIV +1
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] The technical problem to be solved by the present invention is how to detect or evaluate the risk of adverse drug reactions in people responding to levofloxacin

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • New application of HLA-B* 13 gene
  • New application of HLA-B* 13 gene
  • New application of HLA-B* 13 gene

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0059] Example 1, HLA-B*13:01 and / or HLA-B*13:02 alleles are genetic markers of risk of severe drug eruption caused by levofloxacin

[0060] 1. Sample

[0061] 1. Case samples (severe drug eruption group caused by levofloxacin)

[0062] The case samples in this example were 11 patients with severe drug eruption caused by levofloxacin from Huashan Hospital Affiliated to Fudan University in Shanghai, China. These 11 patients received levofloxacin for pulmonary infection, urinary tract infection or other infections. Among the 11 patients, there were 8 males and 3 females, with an average age of 47 years. The time from the start of levofloxacin to the appearance of severe drug eruption symptoms ranged from 1 day to 21 days (average 7.9 days). The 11 patients included 4 SJS, 4 TEN, 1 SJS / TEN overlap, 1 DRESS, and 1 AGEP. The diagnosis of severe drug eruption is based on the patient's medical history, clinical manifestations and laboratory tests.

[0063] 2. Normal control samp...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Sensitivityaaaaaaaaaa
Sensitivityaaaaaaaaaa
Login to View More

Abstract

The invention discloses a new application of an HLA-B* 13: 02 allele. The invention discloses an application of a substance for detecting an HLA-B* 13: 02 allele or a substance for detecting HLA-B* 13: 01 allele and the HLA-B* 13: 02 allele in preparation of a product for detecting or evaluating the adverse drug reaction risk of human responding to levofloxacin or the severe drug rash risk causedby levofloxacin. Experiments prove that alleles of human leukocyte antigen genes, namely HLA-B* 13: 01 and / or HLA-B* 13: 02, are related to severe drug rash risks caused by levofloxacin. HLA-B* 13: 01and / or HLA-B* 13: 02 alleles can be used as marker genes for predicting the occurrence risk of severe drug rash caused by levofloxacin.

Description

technical field [0001] The invention belongs to the technical field of biomedicine, and specifically relates to a new application of the HLA-B*13 gene, in particular to a new application of the HLA-B*13:01 gene and / or the HLA-B*13:02 gene. Background technique [0002] The human leucocyte antigen (HLA) gene system is the human major histocompatibility complex (MHC), which is located on the short arm of chromosome 6 and is composed of a series of closely linked gene loci A genetic complex with a high degree of polymorphism. Its encoded product is leukocyte antigen, which is involved in antigen processing and presentation, and plays an important role in specific immune response and immune regulation. In addition, HLA molecules are also involved in the occurrence of transplant rejection and various pathological processes. [0003] Levofloxacin (Levofloxacin), chemical name ((S)-(-)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7- Oxo-7H-pyrido[1,2,3-de]-[1,4]benz...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/6883
CPCC12Q1/6883C12Q2600/106C12Q2600/136C12Q2600/156C12Q2600/172Y02A50/30
Inventor 邢清和骆肖群杨凡萍
Owner FUDAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com